Understanding Citrullination in Rheumatoid Arthritis
Discover the role of citrullination in the development of rheumatoid arthritis and its importance as a target of the autoimmune response.
Unlocking the power of anti-MCV detection for early diagnosis of Rheumatoid Arthritis
Traditional tests for Rheumatoid Arthritis detect the autoantibodies rheumatoid factor and anti-cyclic citrullinated peptide (CCP). But neither test identifies all patients with the disorder, especially in the early stages when intervention can prevent more serious disease later. This session will discuss the role of citrullination in RA, the evolution of anti-CCP assays, and the search for antibodies to individual citrullinated proteins which may be used to complement anti-CCP in the diagnosis and management of RA. The utility of antibody to the mutated version of citrullinated vimentin will be highlighted.
This webinar is presented in English.
What will you learn?
Limitations of Traditional RA Antibody Testing
Learn why rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) tests do not identify all RA patients, particularly during the early stages of the disease.
The Evolution of Anti-CCP Assays
Explore how anti-CCP testing has evolved over time and how advances in assay design have improved RA diagnosis.
Emerging Biomarkers for Improved Diagnosis
Understand the potential value of antibodies directed against specific citrullinated proteins as complementary tools to anti-CCP testing.
The Clinical Utility of Anti-Mutated Citrullinated Vimentin (Anti-MCV)
Examine the role of anti-MCV antibodies and how they may support the diagnosis and management of rheumatoid arthritis.
Patient care begins and thrives with enhanced diagnostics
About Dr. Holger Bang
Dr. Holger Bang is Project Leader of the Euro TEAM (Towards Early Diagnosis and Biomarker Validation in Arthritis Management) initiative and serves as Senior Scientific Advisor at Sebia.
He previously held the position of Director of Research and Clinical Affairs at ORGENTEC Diagnostika GmbH, now part of the Sebia Group, and was Head of Research & Development at the Protein Folding Lab of the Max Planck Institute in Halle, Germany.
With an extensive scientific track record, Dr. Bang has authored 104 peer-reviewed publications and his work has been cited more than 4,000 times, reflecting his significant contributions to biomarker research and the diagnosis and management of autoimmune diseases, particularly rheumatoid arthritis.
Test associated with this resource
Deepen your expertise with additional webinars
Educational Webinar with Holger Bang, PhD & Roberto Fiorillo
Discover how innovative anti-MCV testing enables early, accurate Rheumatoid Arthritis diagnosis and improves patient outcomes in this expert Medlab podcast
Educational Webinar with Gerd-Rüdiger Burmester, MD & Roberto Fiorillo
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country. Please contact your local Sebia representative. Information intended for healthcare professionals. Carefully read the instructions in the reagent package inserts and instrument manuals.